AstraZeneca searching for Pascal Soriot successor – reportAstraZeneca is looking for a successor to CEO Pascal Soriot just in case he decides to move on, Share XAstraZeneca searching for Pascal Soriot successor – reporthttps://pharmaphorum.com/news/astrazeneca-searching-for-pascal-soriot-successor-report/
Australia extends deadline for My Health Record opt-outAustralia’s health minister Greg Hunt has extended the deadline for opting out of the country’s controversial My Health Share XAustralia extends deadline for My Health Record opt-outhttps://pharmaphorum.com/news/australia-extends-deadline-for-my-health-record-opt-out/
Cosmo’s diarrhoea drug approved, threatening Salix’ cash cowIreland’s Cosmo Pharma claimed FDA approval for its traveller’s diarrhoea drug Aemcolo, which some analysts say could be Share XCosmo’s diarrhoea drug approved, threatening Salix’ cash cowhttps://pharmaphorum.com/news/cosmos-diarrhoea-drug-approved-threatening-salix-cash-cow/
Litmus and NIH study use of wearables in cancer R&DHealth data firm Litmus Health has been awarded a contract with the National Cancer Institute of the US Share XLitmus and NIH study use of wearables in cancer R&Dhttps://pharmaphorum.com/news/litmus-and-nih-study-use-of-wearables-in-cancer-rd/
Novartis’ CAR-T cancer drug available on NHS to young peopleNovartis’ cutting-edge CAR-T therapy Kymriah has officially become available on the NHS for young people with blood cancer. Share XNovartis’ CAR-T cancer drug available on NHS to young peoplehttps://pharmaphorum.com/news/novartis-car-t-cancer-drug-available-on-nhs-to-young-people/
AstraZeneca’s immunotherapy fails in key lung cancer trialAstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line Share XAstraZeneca’s immunotherapy fails in key lung cancer trialhttps://pharmaphorum.com/news/astrazenecas-imfinzi-fails-in-key-lung-cancer-trial/
Blueprint eyes quick filing for GIST drug avapritinibBlueprint Medicines has new data for its lead cancer drug avapritinib in gastrointestinal stromal tumours (GIST) that set Share XBlueprint eyes quick filing for GIST drug avapritinibhttps://pharmaphorum.com/news/blueprint-eyes-quick-filing-for-gist-drug-avapritinib/
Exscientia builds AI capability with Kinetic acquisitionThere is huge focus on the potential of artificial intelligence (AI) in drug discovery – and Exscientia is Share XExscientia builds AI capability with Kinetic acquisitionhttps://pharmaphorum.com/news/exscientia-builds-ai-capability-with-kinetic-acquisition/
Pharma welcomes Brexit agreement amid political chaosThe UK’s pharma industry has welcomed Theresa May’s hard won agreement with EU leaders on Brexit, which is Share XPharma welcomes Brexit agreement amid political chaoshttps://pharmaphorum.com/news/pharma-welcomes-brexit-agreement-amid-political-chaos/
Lilly files new class migraine drug with FDAEli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its Share XLilly files new class migraine drug with FDAhttps://pharmaphorum.com/news/lilly-files-new-class-migraine-drug-with-fda/
Pfizer hit by UK Supreme Court ruling on Lyrica patentPfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to Share XPfizer hit by UK Supreme Court ruling on Lyrica patenthttps://pharmaphorum.com/news/pfizer-hit-by-uk-supreme-court-ruling-on-lyrica-patent/
GSK begins clinical trials of pancreatic cancer combinationGlaxoSmithKline plans to carry out clinical trials on its pancreatic drug hopeful, GSK547, following promising results when treating Share XGSK begins clinical trials of pancreatic cancer combinationhttps://pharmaphorum.com/news/gsk-begins-clinical-trials-of-pancreatic-cancer-combination/
Defined Health becomes Cello Health BioConsultingCello’s US health consulting business Defined Health has been rebranded as Cello Health BioConsulting, following its acquisition by Share XDefined Health becomes Cello Health BioConsultinghttps://pharmaphorum.com/news/cello-health-bioconsulting-defined-health/
AI device could be cheaper and more accurate than smear testsUK startup Lancor Scientific has secured funding to launch a medical device that aims to use artificial intelligence Share XAI device could be cheaper and more accurate than smear testshttps://pharmaphorum.com/news/ai-device-could-be-cheaper-and-more-accurate-than-smear-tests/
Roivant wins $200m backing to expand R&D operationsBiotech startup Roivant has won a further $200 million backing from investors in a financing round valuing the Share XRoivant wins $200m backing to expand R&D operationshttps://pharmaphorum.com/news/roivant-wins-200m-backing-to-expand-rd-operations/
Merck & Co begins US filing of Ebola vaccineMerck & Co has begun a rolling filing in the US of its Ebola Zaire vaccine, known as Share XMerck & Co begins US filing of Ebola vaccinehttps://pharmaphorum.com/news/merck-co-begins-us-filing-of-ebola-vaccine/
AZ sells rights to RSV virus drug to Sobi for $1.5bnAstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for Share XAZ sells rights to RSV virus drug to Sobi for $1.5bnhttps://pharmaphorum.com/news/az-sells-rights-to-rsv-virus-drug-to-sobi-for-1-5bn/
Eyeing Novartis deal, Akcea trumpets lipoprotein drug dataIonis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with Share XEyeing Novartis deal, Akcea trumpets lipoprotein drug datahttps://pharmaphorum.com/news/eyeing-novartis-deal-akcea-trumpets-lipoprotein-drug-data/
3rd Microbiome Movement – Drug Development Europe Share X3rd Microbiome Movement – Drug Development Europehttps://pharmaphorum.com/partner-content/3rd-microbiome-movement-drug-development-europe-2/
Pharmaceutical Microbiology UK Speaker Interview Released from Fresenius Kabi AB Share XPharmaceutical Microbiology UK Speaker Interview Released from Fresenius Kabi ABhttps://pharmaphorum.com/partner-content/pharmaceutical-microbiology-uk-speaker-interview-released-from-fresenius-kabi-ab/
J+D, Pharma Forecasting Experts Partner with Epiphany, Oncology Data Experts Share XJ+D, Pharma Forecasting Experts Partner with Epiphany, Oncology Data Expertshttps://pharmaphorum.com/partner-content/jd-pharma-forecasting-experts-partner-with-epiphany-oncology-data-experts/
Parallel Trade for Pharma: Addressing Competition law and FMD challenges Share XParallel Trade for Pharma: Addressing Competition law and FMD challengeshttps://pharmaphorum.com/partner-content/parallel-trade-for-pharma-addressing-competition-law-and-fmd-challenges/
STEM Healthcare appoints Jason McKenna as CEO Share XSTEM Healthcare appoints Jason McKenna as CEOhttps://pharmaphorum.com/partner-content/stem-healthcare-appoints-jason-mckenna-as-ceo/
Ashfield Healthcare Communications appoints new Global Commercial Director Share XAshfield Healthcare Communications appoints new Global Commercial Directorhttps://pharmaphorum.com/partner-content/ashfield-healthcare-communications-appoints-new-global-commercial-director/
